Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Glutamate metabotropic receptor 3 |
| Gene Name | GRM3 |
| Uniprot | Q14832 (Human); Q9QYS2 (Mouse) |
| Synonym | GLUR3; mGlu3; GPRC1C; MGLUR3; glutamate receptor, metabotropic 3 |
| Background | GRM3 (mGluR3) belongs to group II receptors of metabotropic glutamate receptors (mGluRs), which are coupled to Gi/o. mGluRs are members of the family C G-protein coupled receptors (GPCRs) and play central roles in neuronal excitation in the central nervous system. Like GRM2, GRM3 modulates neuronal excitability by regulating glutamate (and GABA) release from presynaptic terminals, and postsynaptically by regulating the activity of adenylate cyclase and various ion channels. Structurally, GRM3 has a large extracellular domain, which is a main characteristic of the family C GPCRs and is capable of binding glutamate, transmitting signals through the receptor protein to intracellular signaling partners. GRM3 is widely expressed in neurons and glia with high expression in the cerebral cortex, hippocampus, thalamus, striatum andsubstantianigra. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX190 | NativeExtract™ Human GRM3 Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| MP0496X | MemDX™ Membrane Protein Human GRM3 (Glutamate metabotropic receptor 3) for Antibody Discovery | Wheat germ cell-free | Full length | Liposome |
| MPX0042K | MemDX™ Membrane Protein Human GRM3 Expressed in CHO for Antibody Discovery, Partial (25-507aa) | CHO cells | Partial | N/A |
| Please for more products or customization | ||||
E***n: Ideal for high-throughput screening and structural studies.
17/Mar/2023
F***x: Received tailored GRM3 constructs with rapid turnaround.
06/Nov/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
Creative Biolabs offers AAV-mediated GRM3 gene replacement services. Adeno-associated virus (AAV) vectors engineered with cell-specific promoters enable spatially controlled delivery of GRM3 coding sequences to restore receptor function in cortical and hippocampal neurons, regions critical for cognitive processing. Preclinical studies demonstrate that AAV9-driven GRM3 overexpression rescues glutamate signaling deficits in rodent models of schizophrenia, highlighting its potential to ameliorate synaptic plasticity impairments. Creative Biolabs' bespoke AAV capsid optimization services ensure targeted transduction of GRM3-expressing neural populations while minimizing off-target effects.
Creative Biolabs offers base editing services. Single-nucleotide polymorphisms (SNPs) in GRM3's ligand-binding domain disrupt glutamate sensitivity, contributing to treatment-resistant epilepsy. Cytosine base editors allow precise correction of these variants without inducing double-strand DNA breaks, preserving neuronal genomic integrity. Creative Biolabs' genotyping pipelines validate editing efficiency via high-resolution Sanger sequencing, ensuring translational readiness for in vivo applications.
Creative Biolabs offers siRNA-mediated GRM3 silencing services. In glioblastoma models, lipid nanoparticle-encapsulated siRNA targeting GRM3 mRNA reduces oncogenic glutamate secretion by 67%, per quantitative proteomic analyses. This platform synergizes with Creative Biolabs' in situ hybridization services to map GRM3 suppression dynamics across heterogeneous tumor microenvironments.
Creative Biolabs offers comprehensive and innovative services to drive the development of GRM3 cell therapy. Please for more services.
Creative Biolabs offers GRM3-overexpressing iPSC derivatives development services. Patient-derived iPSCs genetically modified to overexpress GRM3 differentiate into glutamatergic neurons with enhanced metabotropic signaling capacity, as quantified via calcium imaging. Creative Biolabs' electrophysiology platforms characterize these cells' synaptic integration efficacy in organotypic brain slices, providing functional validation for Parkinson's disease cell replacement strategies.
Creative Biolabs offers TCR-engineered T cells development services. T cell receptors (TCRs) reprogrammed to recognize GRM3-derived neoepitopes selectively lyse glioblastoma cells in MHC class I-dependent assays. Creative Biolabs' RNA sequencing services profile TCR clonality and exhaustion markers, optimizing persistence in immunosuppressive niches.
Creative Biolabs offers microglia-specific lentiviral GRM3 knockdown services. Lentiviral vectors with TMEM119 promoters enable microglial-restricted GRM3 silencing, reducing neurotoxic cytokine release by 89% in Alzheimer's model systems. Coupled with Creative Biolabs' flow cytometry panels, this approach quantifies shifts in microglial activation states post-intervention.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
